Kazia: AGILE Hurdle Missed but Significant Value Remains
Corporate Connect analyst Marc Sinatra has today released an updated research report for ASX-listed biotech company Kazia Therapeutics (ASX: KZA), now available for download.
Read MoreTag: KZA
Kazia Therapeutics (ASX: KZA) – Webinar presentation
James Garner – CEO & MD – Kazia Therapeutics Limited is an innovative oncology-focused biotechnology company. Kazia is working to develop therapies across a range of oncology indications.
Read MoreKey Points To Remember When Investing in Biotech Companies
As part of his latest research report on the biotech sector, Corporate Connect analyst Marc Sinatra gives some insights into what to consider when making an investment in this space.
Read MoreDue Diligence Webinar – Kazia Therapeutics
Presenter – James Garner CEO & Managing Director – Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company based in Sydney, Australia. Kazia’s pipeline includes two clinical-stage drug development candidates and is working to develop therapies across a range of oncology indications.
Read MoreA high quality pipeline of cancer drugs
James Garner – Managing Director & CEO – Kazia Therapeutics Limited is an innovative oncology-focused biotechnology company. Kazia is working to develop therapies across a range of oncology indications.
Read MoreAlzheimer’s Decision Sends Positive Message to Aussie Biotechs
The US Food and Drug Administration’s approval of a new treatment for Alzheimer’s disease suggests a sea change in the regulator’s attitude to green-lighting novel drugs for difficult-to-treat illnesses.
Read MoreKazia Licenses New Oncology Drug Candidate
Kazia Therapeutics has announced that it has entered into a worldwide exclusive licensing agreement and a master services agreement with Evotec SE, a leading European drug discovery and development company.
Read MoreKazia Licenses Ovarian Cancer Drug to Swedish Pharmaceutical Company
Australian oncology-focused company, Kazia Therapeutics has just announced a license agreement with Swedish speciality pharmaceutical company Oasmia Pharmaceutical for its ovarian cancer drug Cantrixil.
Read MoreKazia Therapeutics (ASX:KZA) – Hidden Gems Webinar Presentation
Presenter – James Garner – Chief Executive Officer & Executive Director – Kazia Therapeutics is an innovative oncology-focused biotechnology company. The company’s pipeline includes two clinical-stage drug development candidates, and they are working to develop therapies across a range of oncology indications.
Read MoreWhy Kazia Therapeutics is Australia’s biotech shining star
Kazia Therapeutics share price has been driven by strong buying in their US-listed ADRs with the company’s market capitalisation moving from $75m to $200m since the Corporate Connect Research report was released. Corporate Connect biotech analyst Marc Sinatra updates the market post the ASX announcement by Kazia of further Paxalisib data.
Read MoreKazia’s New Collaboration Gives Their Cancer Drug New Potential For Treatment Of Lymphoma
CEO of Australian oncology company Kazia Therapeutics Dr James Garner discusses the latest news from the company with Share Café Managing Director Tim McGowen.
Read MoreWith A ‘Ticket To Ride’, Kazia Wows Investors With Its Rare-Cancer Story
Kazia Therapeutics has been trialling its lead drug paxalisib (formerly GDC-0084) to treat the aggressive and complex disease. Paxalisib inhibits a signalling pathway called PI3K which is expressed in 85 per cent to 90 per cent of glioblastoma tumours. After years of quiet development, Kazia in August achieved two key milestones.
Read MoreKazia Therapeutics – ShareCafe Hidden Gems Webinar Presentation
Kazia Therapeutics CEO Dr. James Garner presents at the ShareCafe Hidden Gems Webinar on June 26, 2020. Kazia is an innovative oncology-focused biotechnology company, based in Sydney, Australia. The company’s pipeline includes two clinical-stage drug development candidates, and Kazia is working to develop therapies across a range of oncology indications.
Read More
